uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Regulation of the TGF-beta pathway by deubiquitinases in cancer
Leiden Univ, Med Ctr, Dept Mol Cell Biol, Leiden, Netherlands.;Leiden Univ, Med Ctr, Canc Genom Ctr Netherlands, Leiden, Netherlands..
Leiden Univ, Med Ctr, Dept Mol Cell Biol, Leiden, Netherlands.;Leiden Univ, Med Ctr, Canc Genom Ctr Netherlands, Leiden, Netherlands..
Leiden Univ, Med Ctr, Dept Mol Cell Biol, Leiden, Netherlands.;Leiden Univ, Med Ctr, Canc Genom Ctr Netherlands, Leiden, Netherlands..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Ludwig Institute for Cancer Research. Leiden Univ, Med Ctr, Dept Mol Cell Biol, Leiden, Netherlands.;Leiden Univ, Med Ctr, Canc Genom Ctr Netherlands, Leiden, Netherlands..
2016 (English)In: International Journal of Biochemistry and Cell Biology, ISSN 1357-2725, E-ISSN 1878-5875, Vol. 76, 135-145 p.Article, review/survey (Refereed) Published
Resource type
Text
Abstract [en]

The transforming growth factor-beta (TGF-beta) pathway regulates diverse cellular processes. It signals via serine/threonine kinase receptors and intracellular Smad and non-Smad effector proteins. In cancer cells, aberrant TGF-beta signalling can lead to loss of growth inhibition and an increase in invasion, epithelial-to-mesenchymal transition (EMT) and metastasis. Therapeutic targeting of the pro-oncogenic TGF-beta responses is currently being explored as a potential therapy against certain invasive and metastatic cancer types. The ubiquitin post-translational regulation system is emerging as a key regulatory mechanism for the control of TGF-beta pathway components. In this review, we focus on the role of deubiquitinases (DUBS), which counteract the activity of E3 ubiquitin ligases. We will discuss the mechanisms by which specific DUBs control Smad and non-Smad TGF-beta signalling routes, and how perturbation of the expression and function of DUBs contributes to misregulation of TGF-beta signalling in cancer.

Place, publisher, year, edition, pages
2016. Vol. 76, 135-145 p.
Keyword [en]
TGF-beta, Smad, Ubiquitin, Deubiquitinase, Cancer
National Category
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
URN: urn:nbn:se:uu:diva-300636DOI: 10.1016/j.biocel.2016.05.001ISI: 000378967200015PubMedID: 27155333OAI: oai:DiVA.org:uu-300636DiVA: diva2:951797
Funder
Swedish Cancer Society, 090773
Available from: 2016-08-10 Created: 2016-08-10 Last updated: 2016-08-10Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
Ludwig Institute for Cancer Research
In the same journal
International Journal of Biochemistry and Cell Biology
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 150 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf